Capital One Financial Begins Coverage on Heron Therapeutics (NASDAQ:HRTX)

Capital One Financial started coverage on shares of Heron Therapeutics (NASDAQ:HRTX – Free Report) in a research report sent to investors on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $6.00 price objective on the biotechnology company’s stock. Capital One Financial also issued estimates for Heron Therapeutics’ Q1 2024 earnings at […]

Related Keywords

Monaco , ,Heron Therapeutics Company Profile ,Richmond Brothers Inc ,Needham Company ,Orchard Capital Management ,Heron Therapeutics Inc ,Panagora Asset Management Inc ,Capital One Financial ,Heron Therapeutics ,Free Report ,One Financial ,Get Free Report ,Capital Management ,Asset Management ,Monaco Asset Management ,Heron Therapeutics Daily ,Nasdaq Hrtx ,Hrtx ,Medical ,Initiated Coverage ,Capital One Financial Co ,